AX
AX9.F Akebia Therapeutics Inc
- Market cap
- EUR 132M
- P/E
- -
- P/B
- 7.18x
- ROE
- -211.5%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is AX9.F undervalued?
Graham numberThe Graham number of Akebia Therapeutics Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Akebia Therapeutics Inc fundamental analysis
No fundamental analysis for Akebia Therapeutics Inc yet.
Akebia Therapeutics Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Akebia Therapeutics Inc
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. Its product portfolio includes Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent (DD) and non-dialysis dependent (NDD) patients; and Auryxia, a ferric citrate that is used to control the serum phosphorus levels in…
Full company profileAkebia Therapeutics Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Akebia Therapeutics Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 1.54M | 178M | 208M | 335M | 295M | 214M | 293M | 195M | 160M | 236M | 186M |
| Gross Profit | -114M | -49.7M | 200M | 190M | -601K | 60.2M | 208M | 120M | 97.0M | 197M | 147M |
| Operating Income | -136M | -79.9M | -178M | -286M | -376M | -265M | -63.2M | -46.1M | -50.4M | 23.5M | -25.6M |
| EBITDA | - | -79.3M | -176M | -248M | -343M | - | -40.8M | -8.27M | -13.7M | 21.7M | -26.7M |
| Net Income | -136M | -76.9M | -144M | -280M | -383M | -283M | -92.6M | -51.9M | -69.4M | -5.35M | -43.1M |
| EPS | - | -1.62 | -1.23 | -2.30 | -2.59 | -1.60 | -0.50 | -0.28 | -0.33 | -0.02 | -0.16 |
| Balance Sheet | |||||||||||
| Total Assets | 300M | 364M | 997M | 771M | 644M | 526M | 352M | 242M | 221M | 377M | 342M |
| Total Liabilities | 232M | 245M | 361M | 376M | 397M | 449M | 342M | 272M | 270M | 344M | 322M |
| Shareholders' Equity | 68.1M | 119M | 636M | 395M | 248M | 76.5M | 9.34M | -30.6M | -49.2M | 32.6M | 20.4M |
| Cash & Short-term Investments | 187M | 70.2M | 105M | 147M | 229M | 150M | 90.5M | 42.9M | 51.9M | 185M | 159M |
| Cash Flow | |||||||||||
| Operating Cash Flow | 57.9M | -56.2M | -97.5M | -257M | -110M | -253M | -73.2M | -23.4M | -40.7M | 68.0M | -20.5M |
| Capital Expenditure | 2.66M | 1.62M | 1.61M | 6.66M | 317K | 59.0K | 114K | 0.00 | 33.0K | 8.10M | 9.00M |
| Free Cash Flow | - | -57.8M | -99.1M | -264M | -111M | -253M | -73.3M | -23.4M | -40.7M | 59.9M | -29.5M |
| Ratios | |||||||||||
| ROE | -199.3% | -64.5% | -22.6% | -70.8% | -154.9% | -369.9% | -990.8% | - | - | -16.4% | -211.5% |
| ROA | -45.2% | -21.1% | -14.4% | -36.3% | -59.5% | -53.8% | -26.3% | -21.5% | -31.5% | -1.4% | -12.6% |
| Net Profit Margin | -8,843.5% | -43.2% | -69.1% | -83.5% | -129.9% | -132.4% | -31.6% | -26.7% | -43.3% | -2.3% | -23.2% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Akebia Therapeutics Inc dividends
Akebia Therapeutics Inc has not paid dividends in the last 9 fiscal years.
Who owns Akebia Therapeutics Inc
- Insiders 1.98%
- Institutions 41.63%
- Public & others 56.39%
- Shares outstanding 278M
- Free float 273M
Akebia Therapeutics Inc company profile
- Company name
- Akebia Therapeutics Inc
- Ticker
- AX9.F
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 194
- Fiscal year end
- December
- Address
- 180 Third Avenue, Waltham, MA, United States, 02451
- Phone
- 617 871 2098
- Website
- akebia.com
About Akebia Therapeutics Inc
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. Its product portfolio includes Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent (DD) and non-dialysis dependent (NDD) patients; and Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD and the treatment of iron deficiency anemia in adult patients with NDD-CKD. The company is also developing AKB-9090, which is in Phase 2 clinical trial for treating cardiac surgery-related acute kidney injury and acute respiratory distress syndrome; and AKB-10108 for the treatment of retinopathy of prematurity in neonates. The company has license and collaboration agreements with Tanabe Pharma Corporation for the development and commercialization of Vafseo in Japan and other Asian countries; Vafseo License and Collaboration Agreements; CSL Vifor Agreements; Averoa License Agreement; License Agreement with Panion & BF Biotech, Inc.; Cyclerion Therapeutics License Agreement; and Q32 Asset Purchase Agreement. Akebia Therapeutics, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.
Akebia Therapeutics Inc management
3- Mr. John P. Butler MBACEO, President & Director · born 1964
- Mr. Erik John Ostrowski M.B.A.Chief Business Officer, Senior VP, CFO & Treasurer · born 1972
- Dr. Steven Keith Burke M.D.Senior VP and Chief Research & Development Officer · born 1961